By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cangene bioPharma 

1111 S. Paca Street

Baltimore  Maryland  21230  U.S.A.
Phone: 800-441-4225 Fax: n/a


SEARCH JOBS
Cangene bioPharma performs clinical manufacturing for all regulatory phases. Contracting with Cangene bioPharma or clinical manufacturing has a number of advantages:

1. Because clinical drug substances are frequently expensive and difficult to obtain in quantity, Cangene bioPharma has systems designed to minimize losses, ensuring customers get the maximum amount of finished product possible.

2. Cangene bioPharma has a large selection of pre-qualified vials, stoppers and syringes. Choosing one of the Cangene bioPharma pre-qualified combinations can reduce the time from project initiation to production to two months in most cases.

3. Cangene bioPharma can fill liquid or lyophilized products in vial sizes from 3 to 100 cc and most major syringe sizes.

4. Cangene bioPharma has commercial scale manufacturing and a regulatory profile including approvals by regulatory agencies in multiple countries, allowing for growth and scale-up opportunities as your product progresses through to regulatory approval and commercial distribution.

For more information, please visit: http://www.cangenebiopharma.com/


Key Statistics


Email: info@cangenebiopharma.com
Ownership: Subsidiary

Web Site: Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL))
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL)) Facility Renovation is Complete and Operating at Expanded Capacity 5/3/2011 8:59:14 AM
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL)) To Host First Quarter Fiscal 2010 Conference Call On Tuesday December 15, 2009 At 11:00 A.M. Eastern 4/28/2010 8:59:19 AM
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL)) Announces First Quarter Financial Results For Fiscal 2010; Contract Deliveries Remain On Target And The Company Is Now Increasing Its Focus On The U.S. Commercial Market 4/28/2010 8:58:16 AM
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL)) Receives A Positive Opinion From The European Medicines Evaluation Agency For Hepatitis B Product 4/28/2010 8:57:25 AM
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL)) Announces Second Quarter Financial Results For Fiscal 2010 4/28/2010 8:53:39 AM
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL))'s Hepatitis B product Approved by European Commission 4/28/2010 8:52:18 AM
Health Canada Endorsed Important Safety Information Regarding Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL))'s WinRho(R) SDF (Rho(D) Immune Globulin (Human)) 4/28/2010 8:50:59 AM
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL)) And Barda Extend Botulism Antitoxin Contract 4/28/2010 8:46:33 AM
Cangene bioPharma (Formerly Known as Chesapeake Biological Laboratories, Inc. (CBL)) Assumes U.S. Commercialization Rights for WinRho(R) SDF 4/21/2010 8:53:23 AM
BioSpace Inc. Unveils 2006 BioCapital™ Hotbed Campaign 5/24/2006 7:38:11 PM
//-->